BRIEF-Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B
November 07, 2017 at 07:45 AM EST
* Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B